Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors
This study is ongoing, but not recruiting participants.
Study NCT00003125 Information provided by National Cancer Institute (NCI)
First Received: November 1, 1999 Last Updated: February 6, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Esophageal Cancer
Gastric Cancer
Lung Cancer
Pancreatic Cancer
Additional conditions recognized in this trial
Breast Neoplasms
Esophageal Diseases
Esophageal Neoplasms
Lung Neoplasms
Pancreatic Neoplasms
Stomach Neoplasms
More general conditions related to this trial
Breast Diseases
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Head and Neck Neoplasms
Lung Diseases
Neoplasms
Neoplasms by Site
Pancreatic Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Skin Diseases
Stomach Diseases
Thoracic Neoplasms
Interventions listed in this trial
ALVAC-CEA vaccine
aldesleukin
sargramostim
vaccinia-CEA vaccine
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antineoplastic Agents
Antiviral Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Lombardi Cancer Research Center
National Cancer Institute (NCI)
Back to top of Main Content
